Clinical trials
Erectile Dysfunction trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2011 | 1 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Unknown status | 10 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vigonvita Life Sciences | 10 |
| Eli Lilly and Company | 4 |
| Bayer | 2 |
| Chinese Academy of Sciences | 2 |
| First Affiliated Hospital, Sun Yat-Sen University | 2 |
| Yangtze River Pharmaceutical Group Co., Ltd. | 2 |
| Beijing Inno Medicine Co., Ltd. | 1 |
| Bin Xu | 1 |
| Boston Scientific Corporation | 1 |
| China Rehabilitation Research Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Erectile Dysfunction | 38 |
| Diabetes Mellitus, Type 1 | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Premature Ejaculation | 2 |
| Prostatic Hyperplasia | 2 |
| Pulmonary Arterial Hypertension | 2 |
| Rectal Neoplasms | 2 |
| Atherosclerosis | 1 |
| Hypertension | 1 |
| Median Neuropathy | 1 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.